Dear shareholders
We had a busy first half of the year, with the creation of a leading platform in Rare Blood Disorders, through three consecutive deals: acquiring full global rights of fitusiran, followed by the acquisitions of two biotechnology companies, Bioverativ and Ablynx.
These operations not only allow us to build a leadership position in Rare Blood Disorders but also further strengthens our Research & Development pipeline...
What are the key highlights of the second quarter of 2018?
In the second quarter, we achieved significant milestones in building our new Rare Blood Disorder franchise and internalizing the innovative Nanobody® platform from Ablynx, as we finalized its acquisition in June...
Can you tell us more about the contribution of Dupixent® to the performance of Sanofi?
Dupixent® generated sales of €176M in the second quarter of 2018 compared to €26M in the second quarter of 2017...
Can you comment on the recent and upcoming changes at the Executive Committee level?
We announced important changes in the Executive Committee...
Company sales stable (at CER) in the second quarter
In the second quarter of 2018, company sales were €8,176M, down 5.7% on a reported basis. Exchange rate movements had a negative effect of 5.8 percentage points. At CER, company sales increased 0.1%. They were down 2.5% at CER/CS.
Strong contributions from Specialty Care and Emerging Markets
The contribution to company sales from Specialty Care, Emerging Markets and Consumer Healthcare compensated for the decline of the Diabetes & Cardiovascular, Established Products and Vaccines franchise.
Further information about Second Quarter 2018 Results
Sanofi to refocus two Global Business Units (GBUs)
Sanofi will create a new Primary Care GBU that combines the product portfolios of the existing Diabetes and Cardiovascular (DCV) GBU with Established Products. The new Primary Care unit will focus exclusively on mature markets.
Sanofi will create a second new GBU called China & Emerging Markets. This business will focus on the unique characteristics and tremendous growth opportunities in emerging markets...
Cablivi™ approved in the European Union
Divestiture of Zentiva
Sanofi releases its 2017 Integrated Report
Read the 2017 Integrated Report
Finance – Retirement of Jérôme Contamine and appointment of Jean-Baptiste Chasseloup de Chatillon
Jérôme Contamine, Executive Vice-President, Chief Financial Officer, will retire on September 30, 2018, after having served Sanofi for more than nine years.
Jean-Baptiste Chasseloup de Chatillon will succeed him starting October 1, 2018 and will be a member of the Executive Committee.
Human Ressources – Retirement of Roberto Pucci and appointment of Caroline Luscombe
Roberto Pucci, Executive Vice President, Human Resources, will retire end of December 2018 after having served Sanofi for more than nine years.
Caroline Luscombe will succeed him from October 1, 2018 and will be a member of the Executive Committee.
Primary Care – Departure of Stefan Oelrich and appointment of Dieter Weinand
Stefan Oelrich, Executive Vice President, DCV, will leave Sanofi and join Bayer AG as head of the Pharmaceuticals division.
Sanofi appoints Dieter Weinand as Executive Vice President and member of the Executive Committee (as of November 1, 2018) to lead the new Primary Care GBU.
Further information about Sanofi's Executive Committee
Visit of Sanofi Pasteur's Marcy l'Etoile site « Campus Mérieux »
On June 26, 2018, the Shareholders Committee visited the Sanofi Pasteur site of Marcy l'Étoile in the Lyon region, a center of scientific and industrial expertise for the production of vaccines that are exported worldwide. The Shareholders Committee and Investor Relations team were welcomed by Alain Louvel, Deputy Site Head, and members of the site's leadership team and had the opportunity to visit the biologics' production and quality control buildings.
Watch the video "Making vaccines"
Further information about Sanofi Pasteur
The digital revolution
An exciting opportunity for the healthcare sector
In the past decade, the pace of technological change has been accelerating. The digital revolution offers tremendous opportunity for tomorrow's medical landscape. As technology meets biology, we develop new insights into disease treatment.
Digital solutions offer new advances in care that improve the patient experience. Digital touches all areas of our business and is making us rethink and adapt our model.
More about Artificial Intelligence in Healthcare
More about the Blockchain Technology
More about the Factory of the future
Watch the video "Factory of the future"
The Sanofi Investor Relations team will be happy to welcome you at the 21th edition of Actionaria, Europe's largest exhibition for individual shareholders, on November 22 & 23, 2018 at the Palais des Congrès de Paris 2, Place de la Porte Maillot - 75017 Paris.
Come and join us at Espace "Grandes Cap", Level 2, from 1:00 pm to 8:30 pm CET on Thursday and from 9:30 am to 7:00 pm CET on Friday.
On June 1, 2018, Sanofi had a market capitalization of more than €83bn.